Table 2. Comparison of Clinical Outcomes between Beta-Lactam Group and Glycopeptide Group after Inverse Probability of Treatment Weighting.
| Variables | Beta-lactam group (n=195*) | Glycopeptide group (n=149*) | Odds ratio† (95% CI) | p value | |
|---|---|---|---|---|---|
| Recurrent bloodstream infection, no. (%) | 5 (2.6) | 6 (4.0) | 1.25 (0.33–4.83) | 0.743 | |
| Recurrence within 30 days | 1 (0.5) | 3 (2.0) | 2.86 (0.23–35.46) | 0.414 | |
| Recurrence within 90 days (31 days to 90 days) | 4 (2.1) | 3 (2.0) | 0.84 (0.16–4.48) | 0.835 | |
| Persistent bloodstream infection, no. (%) | 35 (17.9) | 6 (4.0) | 0.28 (0.14–0.60) | <0.001 | |
| ICU admission after infection, no. (%) | 38 (19.5) | 31 (20.8) | 1.35 (0.84–2.17) | 0.217 | |
| Mortality, no. (%) | 31 (15.9) | 59 (39.6) | 1.64 (1.07–2.52) | 0.024 | |
| Death within 7 days | 4 (2.1) | 21 (14.1) | 5.17 (2.08–12.85) | <0.001 | |
| Death within 28 days (8 days to 28 days) | 15 (7.7) | 46 (30.9) | 1.85 (1.15–2.99) | 0.012 | |
| Drug adverse event, no. (%) | 28 (14.4) | 9 (6.0) | 0.47 (0.24–0.91) | 0.025 | |
CI, confidence interval; ICU, intensive care unit.
*A total of 15 cases with insufficient data for adjustment (inverse probability of treatment weighting) were excluded; †The odds ratio for glycopeptide group compared to beta-lactam group was calculated by weighted logistic regression model using inverse probability of treatment weighting.